PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Symptom | C0003467|anxiety |
| Sentences | 14 |
| PubMedID- 25774979 | Interestingly, previous clinical studies have related clinically meaningful anxiety with schizophrenia, and, specifically, with poorer psychosocial function . |
| PubMedID- 26482261 | Diagnosis of anxiety in schizophrenia may be challenging, with positive symptoms obscuring anxiety, lower levels of emotional expressivity and communication impeding diagnosis, and conflation with akathisia. |
| PubMedID- 20643628 | Little is known, however, about the possible roots of social anxiety in schizophrenia or their relationship to social anxiety over time. |
| PubMedID- 26427051 | The presence of concurrent symptoms other than those of the primary disorder: there is a high prevalence of affective and anxiety symptoms in patients with schizophrenia, so patients may benefit from antidepressant and anxiolytic treatment. |
| PubMedID- 24669212 | Some disorders, including panic disorder, bipolar disorder and schizophrenia – all associated with anxiety symptoms – exhibit downregulation of platelet and/or lymphocyte tspo . |
| PubMedID- 23771406 | anxiety in schizophrenia possesses specific features and is difficult to assess because no specific evaluating tool is currently available. |
| PubMedID- 24587038 | However, non-selective beta-blockers (e.g., propranolol) could also be used as adjuvants in controlling symptomatic anxiety of patients with schizophrenia . |
| PubMedID- 25834542 | Co-morbid anxiety disorders in patients with schizophrenia in a tertiary institution in south east nigeria: prevalence and correlates. |
| PubMedID- 24948859 | Central nervous system (cns) disorders such as anxiety, insomnia, schizophrenia and epilepsy are widely seen in population worldwide. |
| PubMedID- 21276244 | Exclusion criteria included: current major depressive or anxiety disorder; life-time diagnosis of bipolar disorder; schizophrenia or dementia; moderate to severe depression as determined by the center for epidemiologic studies depression scale (ces-d); currently (in previous 30 days) using any tobacco dependence treatment program; have used an investigational drug within the past 30 days; history of alcohol or drug abuse or dependence as assessed using the cage questionnaire and the drug abuse screening test 20 (dast-20); pregnant, lactating, or likely to become pregnant during the medication phase and not willing to use contraception; history of any major cardiovascular event in the past 6 months; an ecg with significant arrhythmias or abnormal conduction; currently taking medications known to interact with methylphenidate and not able to stop the medication during the study period; uncontrolled hypertension (> 160/100) or tachycardia (heart rate > 110); another household member participating in the study; known allergy to methylphenidate or its constituents; and a specific medical condition in which use of methylphenidate is contraindicated. |
| PubMedID- 25423603 | In these past 2 years, two compounds (the anticonvulsant/anxiolytic pregabalin and the atypical antipsychotic quetiapine) were on phase iii/iv clinical trials for schizophrenia, with comorbid anxiety as a primary outcome measure. |
| PubMedID- 25826365 | anxiety associated with schizophrenia may be attenuated with the use of benzodiazepines; however, their efficacy as an anxiolytic varies widely and they are used on a limited basis . |
| PubMedID- 22832905 | This expression pattern could serve as a biomarker to predict anxiety and the development of associated schizophrenia if further studies confirm our findings. |
| PubMedID- 21208586 | L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. |
Page: 1